Dignitana AB Cash Flow Conversion Efficiency
Dignitana AB cash flow conversion efficiency. Based on the latest financial reports, Dignitana AB (DIGN) has a cash flow conversion efficiency ratio of -0.115x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-495.00K ≈ $-53.27K USD) by net assets (Skr4.29 Million ≈ $462.10K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Dignitana AB (2008–2024)
Cash flow conversion efficiency of Dignitana AB from 2008 to 2024. This chart illustrates how Dignitana AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Dignitana AB stock price today for real-time trading data and today's change.
Dignitana AB Cash Flow Conversion Ratio Explained
Dignitana AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dignitana AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dignitana AB ranked by their cash flow conversion efficiency. Also see DIGN company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KLX Energy Services Holdings Inc
NASDAQ:KLXE
|
-0.224x |
|
SynCore Biotechnology Co Ltd
TWO:4192
|
-0.028x |
|
Legend Mining Ltd
AU:LEG
|
-0.023x |
|
AVTECH Sweden AB Series B
ST:AVT-B
|
0.012x |
|
GWR Group Ltd
AU:GWR
|
0.020x |
|
Southern Energy Corp
V:SOU
|
0.062x |
|
Silvair Inc
WAR:SVRS
|
0.046x |
|
Vulcan Infrastructure and Power Inc.
NASDAQ:VIP
|
0.076x |
Annual Cash Flow Conversion Efficiency for Dignitana AB (2008–2024)
The table below shows the annual cash flow conversion efficiency of Dignitana AB from 2008 to 2024. Review Dignitana AB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr7.11 Million ≈ $765.58K |
Skr373.00K ≈ $40.14K |
0.052x | +106.63% |
| 2023-12-31 | Skr7.26 Million ≈ $781.72K |
Skr-5.74 Million ≈ $-618.15K |
-0.791x | -5.57% |
| 2022-12-31 | Skr24.25 Million ≈ $2.61 Million |
Skr-18.16 Million ≈ $-1.95 Million |
-0.749x | +46.76% |
| 2021-12-31 | Skr31.19 Million ≈ $3.36 Million |
Skr-43.87 Million ≈ $-4.72 Million |
-1.407x | -412.70% |
| 2020-12-31 | Skr77.64 Million ≈ $8.35 Million |
Skr-21.30 Million ≈ $-2.29 Million |
-0.274x | +44.68% |
| 2019-12-31 | Skr55.10 Million ≈ $5.93 Million |
Skr-27.33 Million ≈ $-2.94 Million |
-0.496x | -32.15% |
| 2018-12-31 | Skr54.97 Million ≈ $5.92 Million |
Skr-20.63 Million ≈ $-2.22 Million |
-0.375x | +42.63% |
| 2017-12-31 | Skr51.15 Million ≈ $5.50 Million |
Skr-33.47 Million ≈ $-3.60 Million |
-0.654x | -19.45% |
| 2016-12-31 | Skr55.87 Million ≈ $6.01 Million |
Skr-30.61 Million ≈ $-3.29 Million |
-0.548x | -4.30% |
| 2015-12-31 | Skr40.79 Million ≈ $4.39 Million |
Skr-21.42 Million ≈ $-2.31 Million |
-0.525x | -161.33% |
| 2014-12-31 | Skr14.58 Million ≈ $1.57 Million |
Skr-2.93 Million ≈ $-315.31K |
-0.201x | +65.34% |
| 2013-12-31 | Skr28.14 Million ≈ $3.03 Million |
Skr-16.31 Million ≈ $-1.76 Million |
-0.580x | -33.79% |
| 2012-12-31 | Skr27.39 Million ≈ $2.95 Million |
Skr-11.87 Million ≈ $-1.28 Million |
-0.433x | +54.53% |
| 2011-12-31 | Skr9.32 Million ≈ $1.00 Million |
Skr-8.88 Million ≈ $-955.95K |
-0.953x | +22.45% |
| 2010-12-31 | Skr12.98 Million ≈ $1.40 Million |
Skr-15.96 Million ≈ $-1.72 Million |
-1.229x | +36.89% |
| 2009-12-31 | Skr7.41 Million ≈ $797.86K |
Skr-14.44 Million ≈ $-1.55 Million |
-1.947x | -589.88% |
| 2008-12-31 | Skr3.96 Million ≈ $425.84K |
Skr1.57 Million ≈ $169.28K |
0.398x | -- |
About Dignitana AB
Dignitana AB (publ), a medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally. It offers DigniCap, a scalp cooling system used to reduce hair loss from chemotherapy treatments, as well as for patients receiving chemotherapy to treat other solid tumors. The company was incorporated in 2007 is headquarter… Read more